Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria

The 2007 American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) joint guidelines defined criteria for HER2 positivity of tumors that modified those of the US Food and Drug Administration (FDA), causing some confusion and uncertainty among clinicians. Using data from th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Perez, Edith A., Dueck, Amylou C., McCullough, Ann E., Reinholz, Monica M., Tenner, Kathleen S., Davidson, Nancy E., Gralow, Julie, Harris, Lyndsay N., Kutteh, Leila A., Hillman, David W., Jenkins, Robert B., Chen, Beiyun
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2012
Assuntos:
Brief Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3260130/
https://ncbi.nlm.nih.gov/pubmed/22138096
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djr490
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados